2023-510017-26-00RecruitingPhase 1
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Apr 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- First submitted
- 17 May 2024
- Start date
- 2 Oct 2024
- Lead sponsor
- Celltrion Inc.
- Diseases
- Melanoma
- EU CT number
- 2023-510017-26-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 83
- 16 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose stage IIB, IIC or III melanoma has been completely removed by surgery. It compares three forms of pembrolizumab given after surgery.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Melanoma at stage IIB, IIC or III, completely removed by surgery
Read by machine on 9 Nov 2026.
Sites (16)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Catala d'Oncologia | Badalona | Spain | Active, not recruiting |
| Hospital Universitari Dexeus Grupo Quironsalud | Barcelona | Spain | Active, not recruiting |
| Hospital San Pedro De Alcántara | Cáceres | Spain | Active, not recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Active, not recruiting |
| Hospital Universitario Virgen de la Victoria | Málaga | Spain | Active, not recruiting |
| Parc Tauli Hospital Universitari | Sabadell | Spain | Active, not recruiting |
| Hospital Universitario Marqués de Valdecilla | Santander | Spain | Active, not recruiting |
| Hospital Universitario de Torrejon | Torrejón de Ardoz | Spain | Active, not recruiting |
| Specijalna Bolnica Medico | Rijeka | Croatia | Withdrawn |
| Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l | Meldola | Italy | Completed |
| Azienda Ospedaliera Universitaria Senese | Siena | Italy | Completed |
| Uniwersyteckie Centrum Kliniczne | Gdansk | Poland | Active, not recruiting |
| Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti | Bucharest | Romania | Active, not recruiting |
| Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca | Cluj-Napoca | Romania | Active, not recruiting |
| Centrul De Oncologie SF Nectarie S.R.L. | Craiova | Romania | Active, not recruiting |
| Institute of Oncology Ljubljana | Ljubljana | Slovenia | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.